Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Within the DNA damage repair (DDR) network, DNA polymerase theta (POLQ) has evolved from a "non-canonical repair enzyme" into a critical target for next-generation synthetic lethality drug development. Particularly in the context of homologous recombination deficiency (HRD) tumors, the POLQ-driven theta-mediated end joining (TMEJ) pathway serves as an alternative route for maintaining genomic stability. Its aberrant activation is directly associated with tumor survival, genomic instability, and resistance to PARP inhibitors.
Building on extensive expertise in DDR target research, Creative Biogene has established an integrated drug discovery platform that encompasses POLQ dual-domain functionality, pathway mechanisms, synthetic lethality validation, and translational applications. We provide global biotech and pharmaceutical companies with systematic solutions ranging from target validation to lead optimization.
POLQ is a bifunctional enzyme: its C-terminal domain possesses DNA polymerase activity, while its N-terminal domain exhibits DNA-dependent ATPase/helicase activity. This unique structural architecture defines its central role in the TMEJ pathway, distinguishing it from classical non-homologous end joining (NHEJ) and homologous recombination (HR).
Figure 1. POLQ limits RAD51 filament assembly via its ATPase and RAD51-binding domains, and in HR-deficient contexts it drives alt-EJ repair while its loss leads to cell death.
Accumulating evidence indicates that POLQ not only participates in DNA double-strand break repair but also promotes mutation accumulation during error-prone repair, thereby driving tumor evolution. This dual "repair-mutation" attribute makes POLQ a highly attractive target for drug development. Notably, in HRD backgrounds (e.g., BRCA1/2 mutations), POLQ inhibition induces robust synthetic lethality, offering a novel therapeutic strategy to overcome PARP inhibitor resistance.
However, compared to PARP, POLQ remains at an early stage of development, with core challenges including:
Distinct from conventional service models offering only single enzymatic activity assays or kits, our platform provides a "panoramic dissection" of POLQ function grounded in mechanistic understanding.
The therapeutic potential of POLQ inhibition extends far beyond BRCA1/2. Any homologous recombination (HR) pathway defect can create a synthetic lethal dependency on POLQ. Our platform supports systematic validation across a broad panel of HR associated genes, including:
We systematically integrate detection capabilities for both core domains of POLQ, ensuring drug screening is no longer confined to a single site of action:
This design directly addresses the industry-wide issue of "domain bias screening," enabling precise mechanistic classification of candidate molecules at an early stage.
The true therapeutic value of POLQ extends beyond its enzymatic activity to the TMEJ pathway it drives.
We have established a multi-tiered TMEJ activity assessment system, including:
This system directly evaluates the impact of inhibitors on DNA repair pathway choice, thereby predicting their authentic mechanisms of action in tumors.
Creative Biogene extends further downstream with a dedicated POLQ-HRD synthetic lethality validation platform.
For lead drug screening, we provide a complete workflow from HTS to mechanistic elucidation:
High-Throughput Screening (HTS)
We provide a robust HTS platform that combines fluorescence- and luminescence-based enzymatic activity screening with a dual-channel strategy targeting both ATPase and polymerase activities, all supported by automated 96/384-well systems.
Hit Validation & Mechanism Deconvolution
Following primary screening, hits undergo rigorous validation including IC50/EC50 determination, target binding assessment, domain selectivity profiling, and evaluation of impact on DNA repair pathways.
Resistance Mechanism Analysis
To address critical challenges, we analyze alternative repair pathway activation, conduct gene expression and pathway reprogramming studies, and construct long-term treatment-induced resistance models.
Combination Strategy Development
Recognizing that the core clinical value of POLQ lies in combination therapy, we systematically assess POLQ + PARP inhibitors (to overcome resistance), POLQ + ATR/DNA-PK inhibitors, and DNA-damaging agent combinations. This systematic screening identifies synergistic effects and optimizes therapeutic windows.
You want results you can trust, without endless back and forth. You need data that drives decisions, not just raw numbers. And you need a partner who moves at your pace.
Here's what that looks like with us:
Speed without cutting corners
Most projects move from target to lead confirmation in weeks. Timelines flex with your urgency.
Actionable, integrated reports
No data dumps. You get enzyme, cell, and pathway insights combined with clear go/no go recommendations and a ranked hit list.
Full dual domain coverage
We screen both polymerase and ATPase activities side by side, so you never miss a promising inhibitor because of assay bias.
Real synthetic lethality validation
Using BRCA null, CRISPR engineered HRD models, and patient derived cells, we show you the true synthetic lethal window – dose by dose.
Work the way you want
Single assay, modular package, or full discovery collaboration. Pay for what you need, pivot when you need to.
As PARP inhibitors enter a mature phase, POLQ represents the next wave of innovation in DDR-targeted therapy. Its synthetic lethality potential in HRD tumors and key role in resistance mechanisms make POLQ a strategically valuable target. Creative Biogene is committed to helping clients transition from "recognizing POLQ value" to "realizing POLQ drugs," accelerating the development of next-generation precision anticancer therapeutics.
1. How can I determine whether my project is suitable for targeting POLQ?
POLQ is not equally relevant across all tumor types. Its most well-established application lies in tumors with homologous recombination deficiency (HRD), such as those harboring BRCA1/2 mutations or impaired HR pathway function.
For projects where HRD status has not yet been defined, we recommend prioritizing HRD profiling alongside preliminary assessment of POLQ dependency to evaluate the presence of a therapeutically exploitable synthetic lethality window.
In addition, for models that have developed resistance to PARP inhibitors, POLQ is often considered a high-priority alternative target due to its role in compensatory DNA repair mechanisms.
2. If I already have lead compounds, do I need to restart from enzyme activity screening?
Not necessarily. For projects with existing lead compounds, we typically adopt a mechanism-driven validation workflow rather than repeating primary screening. This approach includes:
This strategy significantly shortens development timelines and avoids unnecessary investment in mechanisms with low relevance to POLQ biology.
3. How can false positives or non-specific inhibition be avoided in POLQ inhibitor screening?
This is a common yet often underestimated challenge in POLQ-related projects. Due to POLQ's dual roles in nucleic acid binding and enzymatic catalysis, certain compounds may generate false-positive signals through non-specific DNA binding or assay interference.
To address this, we implement a multi-layered validation strategy:
By systematically deconvoluting mechanism-related artifacts, we ensure that identified hits possess genuine drug development potential.
References:
Copyright © Creative Biogene. All rights reserved.